Galderma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Switzerland · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
Zahlerweg 10, Zug, Zug, 6300, Switzerlan...Phone Number
+41 584558592Website
www.galderma.comRevenue
$5.2 BillionStock Symbol
GALDIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
1
1
About Galderma
Galderma is a global dermatology company focused exclusively on skin health, combining scientific innovation with consumer‑ and patient‑driven solutions. It develops and markets a comprehensive range of products and treatments across three main business areas injectable aesthetics, dermatological skincare, and therapeutic dermatology to address both cosmetic and medical skin conditions. Galderma partners closely with healthcare professionals worldwide to deliver science‑based care tailored to individual skin needs, from daily skincare and aesthetic treatments to prescription therapies. With a broad international presence and a heritage rooted in dermatological research, the company aims to advance skin health for people across different stages of life.Explore more
Galderma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Galderma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Galderma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Galderma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Galderma
Funding: Get notified immidiatlly once Galderma has new funding data
Check if Galderma has recently received funding, and reach out quickly before it becomes old news!
Check out if Galderma is spiking on competitors!
Click to see if Galderma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Galderma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Galderma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Galderma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Galderma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Galderma.
Galderma Tech Stack
A closer look at the technologies used by Galderma
See more technologies
Most Recent Scoops
Pain Point
Galderma has stated that the timing of the FDA resubmission for Relfydess remains unknown, with an FDA meeting expected sometime in autumn to discuss the remediation plan, and has noted that the capital markets day has been delayed to Q1 next year to allow time to work through the FDA response and provide a better basis for midterm guidance discussion.
Pharmaceuticals
Pain Point
Galderma has received a Complete Response Letter (CRL) from the US FDA for relabotulinumtoxinA (Relfydess), citing remaining observations on the manufacturing site and on analytical method, organization, and optimization, though the company has stated these observations do not relate to the product's safety or efficacy and that it remains fully committed to resolving these topics promptly.
Compliance
Project
Galderma has been named for inclusion in the Swiss Market Index, with the recognition expected to become effective in September.
Product Launch
Galderma has launched Relfydess in three additional international markets in Q2, including Hong Kong as the first Asian market, with the product now approved in 33 markets and additional regulatory filings underway.
Product Launch
Earnings
Earnings, Finance
Galderma News & Media
Galderma expands Cetaphil's Nourishing Line with new body care innovations, delivering clinically proven glow through advanced barrier science
Developed specifically for sensitive skin, the Nourishing & Hydrating Lotion and Cream combine hyaluronic acid and skin-essential lipids to strengthen the skin barrier while delivering clinically proven glow. Builds on the successful launch of the Cetaphil Nourishing Oil-to-Foam facial...Galderma Group AG (GALDY) Q2 2026 Earnings Call Transcript
Galderma Group AG (GALDY) Q2 2026 Earnings Call July 23, 2026 7:00 AM EDTCompany ParticipantsEmil Ivanov - Head of Strategy, Investor Relations &...One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative...Partners Group exits Galderma stake as BDC, REIT deals move over $850m
BDCs struck new lending partnerships and credit facilities on Monday as a publicly traded REIT agreed to sell a portfolio valued at more than $500m.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Galderma
Sign Up For FreeTo access detailed company insights
Galderma is a global dermatology company focused exclusively on skin health, combining scientific innovation with consumer‑ and patient‑driven solutions. It develops and markets a comprehensive range of products and treatments across three main business areas injectable aesthetics, dermatological skincare, and therapeutic dermatology to address bot... Read More
